Navigation Links
Quincy Bioscience Earns NSF Good Manufacturing Practice (GMP) Registration for Facilities
Date:7/18/2013

Madison, WI (PRWEB) July 18, 2013

Quincy Bioscience announced today that its Pinehurst manufacturing facility is now a Good Manufacturing Practices (GMP) facility registered by NSF International.

Earning GMP registration from NSF International verifies that Quincy Bioscience’s facility has the proper methods, equipment, facilities, and controls in place for producing dietary supplement products. The NSF GMP’s were developed in accordance with the U.S. Food and Drug Administration’s (FDA) 21 CFR part 111 regulation on dietary supplement manufacturing, packaging, and distribution. Utilizing GMP guidelines assists companies in developing and maintaining proper controls in their manufacturing process so that products are processed, manufactured and labeled in a consistent manner, and meet quality standards.

"Earning NSF GMP registration for their Pinehurst manufacturing facility provides Quincy Bioscience with a system for continual improvement, as well as demonstrates to customers and supply chain partners their commitment to quality and safety," said Ed Wyszumiala, General Manager of NSF International’s Dietary Supplement programs.

"We’re proud to achieve this recognition of our manufacturing facilities," says Mark Underwood, President of Quincy Bioscience. "We take good manufacturing practices very seriously, and we look forward to continuing our practice of excellence."

Quincy Bioscience manufactures Prevagen, the #1 selling brain health supplement in chain drug pharmacies. Prevagen contains the main ingredient 'apoaequorin', a protein originally discovered in a jellyfish which is used to improve mild memory loss associated with aging.

For more information about Quincy Bioscience, please visit the website.

Read the full story at http://www.prweb.com/releases/PrevagenManufacturer/NSFQualityProduction/prweb10937619.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
2. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
3. Eagle Biosciences Introduces Highly Sensitive Calprotectin ELISA Assay Kit
4. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
5. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
6. PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
7. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
8. Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego
9. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
10. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
11. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... 2017  SeraCare Life Sciences, Inc., a manufacturer ... diagnostics manufacturers and clinical laboratories, is announcing ... Inherited Cancer reference material for ... sequencing (NGS). The Seraseq™ Inherited Cancer DNA Mix ... industry experts to validate the ability of ...
(Date:3/23/2017)... Calif., March 23, 2017  BioPharmX Corporation (NYSE ... for the dermatology market, today reported financial results ... 2017, and will provide an update on the ... year. "We are pleased to report ... for BioPharmX," said President Anja Krammer. "We achieved ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):